Thus, packaging of the DI RNA would prevent packaging of the segment from which it was RAD001 in vivo derived and would very efficiently render that virus particle non-infectious. The data presented here also indicate that adaptive immunity is not required for prevention of acute infection in SCID mice but is needed to prevent disease breaking out later. This was not
due to genome competition between the segment 1 DI RNA and its cognate full-length segment. In other experiments we have found that 244 RNA fully protects type I interferon receptor null mice from disease resulting from A/WSN infection [49]. However, the possibility that interferon also plays a role in DI-mediated protection of SCID mice has yet to be determined. We thank Sam Dixon and her staff for technical help. The Wellcome Trust, the UK Medical Research Council and the Mercia Spinner Fund provided financial support. “
“Simultaneous administration 5-Fluoracil cell line of vaccines in the same visit to a health service is recommended as a strategy to avoid the loss of opportunities for vaccination [1]. A minimum of four weeks
is recommended between doses of different live attenuated vaccines [2]. The Brazilian National Immunization Program (PNI) recommended against intervals shorter than 15 days between the yellow fever vaccine and other live attenuated vaccines for lack of information regarding the interference between these antigens [3]. The Advisory Committee on Immunization Practices (ACIP, Centers for Disease Control and Prevention) recommends that injectable or nasally administered live vaccines be given on the same day or ≥4 weeks apart, to minimize the potential risk for interference [4]. The World Health Organization (WHO) strongly
recommends the yellow fever vaccine at nine months of age, at the same time of the measles vaccine in routine second immunization in endemic areas [5]. The high immunogenicity of substrains 17DD yellow fever vaccine was confirmed in recent studies in adults and children over 2 years of age [6] and [7]. A study with children of 9 months showed no interference when measles and yellow fever vaccines were administered simultaneously [8]. In contrast, a multicenter study in children aged 6–23 months showed a rate of seroconversion and geometric mean titers (GMTs) significantly lower than those of adults. The data suggested that simultaneous vaccination against yellow fever and measles could interfere with the immune response against yellow fever (at that time a monovalent measles vaccine was administered at 9 months of age) [6]. In Brazil and other countries the measles vaccine is currently used in combination with the vaccine against rubella and mumps. There are no published data on the interference of the yellow fever vaccine (YFV) and the rubella and mumps vaccines [9].